Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

The human genome encodes 538 protein kinases that transfer a γ-phosphate group from
ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing (EGFR m) and T790M …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

ATP-binding cassette (ABC) transporters represent one of the largest and oldest families of
membrane proteins in all extant phyla from prokaryotes to humans, which couple the energy …

For most patients with chronic myeloid leukemia, tyrosine kinase inhibitors (TKIs) have
turned a fatal disease into a manageable chronic condition. Imatinib, the first BCR-ABL1 TKI …

The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has
been a model for cancer therapy development. Though most patients with CML have a …

Purpose: Non–small cell lung cancers (NSCLCs) harboring ALK gene rearrangements
(ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) …